Omni Partners US’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Omni Partners US’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$2M	Buy	+201,249	New	+$2M	0.1%	147

Other funds holding PRDS

Arena Capital Advisors Los Angeles, California $200M AUM 6.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

JCM

JS Capital Management New York $223M AUM 104.76% 1-Year Est. Return

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return

Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return

Omni Partners US's PRDS Position: Q3 2021 in Review

Omni Partners US opened a new position in Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2021: 201,249 shares worth $2M. The stake represents 0.1% of the portfolio and ranks #147 among its holdings.

61 funds tracked by Wall St. Rank hold PRDS as of Q3 2021.

Omni Partners US held 201,249 shares of Pardes Biosciences, Inc. Common Stock worth $2M as of Q3 2021.
Pardes Biosciences, Inc. Common Stock was a new Omni Partners US position in Q3 2021.
Pardes Biosciences, Inc. Common Stock made up 0.1% of Omni Partners US's portfolio in Q3 2021, its #147 holding.
61 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2021.

Based on Omni Partners US's 13F filing for Q3 2021, filed 15 Nov 2021.